Key Investor Signals
Co-founder scaled Twentify to 100+ customers and 210,000+ users
Çağlar Bozkurt co-founded Twentify in 2014; by 2016 it had 100+ enterprise customers and 210,000+ app users, showing prior software scale-up experience.
Research collaboration with leadXpro on membrane proteins
Orbion and Swiss structural-biology specialist leadXpro are testing Astra AI models to improve work on difficult membrane proteins, combining Orbion’s ML with leadXpro’s experimental platform.
Prospective FGF21 test doubled usable concentration
In a prospective n=1 FGF21 comparison, Orbion’s design concentrated to 1.4 mg/mL versus 0.7 mg/mL for the literature construct, despite producing 2.4× less purified protein.
Other Positive Signals
- Benchmarked Astra models across 18,367 proteins in five 2026 protein-family studies.
- Raised €100,000 from Antler in January 2025
- ISO/IEC 27001 certified with EU-hosted customer data processing.
- Received Nucleate Germany’s 2026 Scientific Excellence Award.
- QAI Ventures invested in Orbion through its Swiss accelerator in January 2026.
- Selected for QAI Ventures' 2026 Swiss quantum and AI accelerator cohort.
Team
Aniruddh Goteti
Co-Founder and Co-CEO
- Built production machine-learning systems at Blue Yonder, applying AI to enterprise supply-chain software.
- Holds an MSc in Computer Science from Blekinge Institute of Technology and a 2024 MBA from WHU.
- Chaired the WHU Entrepreneurship Roundtable, leading a seven-person MBA team and building its founder community.
Çağlar Bozkurt
Co-Founder
- Co-founded Twentify, which by 2016 had reached 100+ enterprise customers and 210,000+ app users.
- Led product growth at Taxfix, driving 30% more referral purchases and over 20% higher visit-to-registration conversion.
- Served as Senior Product Manager at AMBOSS, bringing direct experience building software for healthcare professionals.
Product
Orbion scores protein sequences before lab work, predicting expression, stability and developability so teams can choose what to make and which mutations to test. It also generates literature-grounded experimental protocols for selected constructs.
Protein construct ranking
Scores candidate sequences for predicted expression, solubility and aggregation risk, helping teams prioritize the strongest constructs before committing time and resources to laboratory production.
Mutation stability prediction
Ranks point mutations by predicted impact on thermal stability and folding, helping teams identify substitutions most likely to improve protein stability before experimental screening.
Lab protocol generation
Builds literature-grounded protocols covering vector choice, expression host and key production steps, giving researchers a practical starting plan for selected protein constructs.
Market Overview
Protein engineering often requires repeated rounds of design, expression and testing before a stable, usable construct is found. The bottleneck is especially acute for membrane proteins and other hard-to-express targets, where failed experimental cycles consume time and specialist lab capacity.
Commercial adoption is emerging among biotech and pharma teams. Cradle reported 21+ customers, including Novo Nordisk and Johnson & Johnson Innovative Medicine, before raising a $73M Series B in 2024. It also reported 1.2–12× faster R&D and cost reductions of up to 90% across customer projects.
Biologics accounted for 51% of U.S. drug spending in 2024, despite only 5% of prescriptions.
Cradle reports AI protein engineering cut project costs by up to 90% across customer programs.
Grand View Research projects the global protein-engineering market to reach $7.6B by 2030.
Cradle raised $73M in 2024 after growing to 21+ customers using its AI protein-engineering platform.
Comparable Outcomes
Absci
Absci built an integrated drug-creation platform combining synthetic biology and AI to discover and engineer protein therapeutics. Absci listed on Nasdaq in July 2021 at $16 per share, implying an IPO valuation of about $1.45B.
Codexis
Codexis developed engineered enzymes and its CodeEvolver platform for biocatalysis, including pharmaceutical manufacturing. Codexis listed on Nasdaq in April 2010 at $13 per share, implying an IPO valuation of about $443M.
Interested in More Startups Like Orbion?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.